Fujifilm Cellular Dynamics, Inc. (FCDI), a US subsidiary of Fujifilm Corporation and a developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, has announced an investment of about $21 million to open a new cGMP-compliant production facility with the goal of industrializing iPS cell manufacturing for regenerative medicine therapies. The facility will support FCDI’s internal cell therapeutics pipeline and will also serve as a contract development and manufacturing organization (CDMO) for iPS cell products.

With the facility slated to be operational by March 2020, FCDI intends to accelerate the development of its internal pipeline in areas such as age-related macular degeneration, retinitis pigmentosa, Parkinson’s disease, heart diseases, and cancer.

Source: Fujifilm Cellular Dynamics